551 related articles for article (PubMed ID: 28978219)
1. Epidemiology and management of hyperlipidemia.
Karr S
Am J Manag Care; 2017 Jun; 23(9 Suppl):S139-S148. PubMed ID: 28978219
[TBL] [Abstract][Full Text] [Related]
2. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
Last AR; Ference JD; Menzel ER
Am Fam Physician; 2017 Jan; 95(2):78-87. PubMed ID: 28084704
[TBL] [Abstract][Full Text] [Related]
3. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
4. Beyond statins: lipid management to reduce cardiovascular risk.
Schuck RN; Mendys PM; Simpson RJ
Pharmacotherapy; 2013 Jul; 33(7):754-64. PubMed ID: 23606278
[TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Hypercholesterolemia in 2015.
Aronow WS
Am J Ther; 2017; 24(2):e121-e129. PubMed ID: 26422823
[TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
9. Evolocumab: A Review in Hyperlipidemia.
Keating GM
Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
[TBL] [Abstract][Full Text] [Related]
10. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
[TBL] [Abstract][Full Text] [Related]
11. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
12. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
Santos RD
Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering agents.
Ewang-Emukowhate M; Wierzbicki AS
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
[TBL] [Abstract][Full Text] [Related]
14. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
Hegele RA; Gidding SS; Ginsberg HN; McPherson R; Raal FJ; Rader DJ; Robinson JG; Welty FK
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2269-80. PubMed ID: 26376908
[TBL] [Abstract][Full Text] [Related]
15. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
16. [Statins and diabetic hyperlipidemia].
Vergès B
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):128-32. PubMed ID: 11240415
[TBL] [Abstract][Full Text] [Related]
17. New Therapies for Primary Hyperlipidemia.
Aguilar-Salinas CA; Gómez-Díaz RA; Corral P
J Clin Endocrinol Metab; 2022 Apr; 107(5):1216-1224. PubMed ID: 34888679
[TBL] [Abstract][Full Text] [Related]
18. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
Kones R; Rumana U
Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
[TBL] [Abstract][Full Text] [Related]
20. [New approaches for the treatment of dyslipidemia].
Mostaza JM; Lahoz C
Med Clin (Barc); 2014 Apr; 142(7):306-9. PubMed ID: 23768860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
